共享决策在遗传性血管管理中的有用性
Rachel Odin1, John Anderson2, Joshua Jacobs3
1From the Department of Internal Medicine, University of Cincinnati College of Medicine, Cincinnati, Ohio.
Allergy and asthma proceedings
|November 9, 2024
概括
共享决策 (SDM) 有效地指导遗传性血管 (HAE) 患者选择最佳疗法. 这种方法确保患者了解治疗选择,从而导致协作治疗选择和改善HAE管理.
科学领域:
- 免疫学 免疫学 免疫学
- 医疗保健服务研究 医疗服务研究
- 以患者为中心的护理
背景情况:
- 遗传性血管 (HAE) 提出了复杂的治疗选择.
- 共享决策 (SDM) 对于将患者偏好与HAE疗法结合起来至关重要.
- 需要一个经过验证的工具来评估患者对HAE护理中的SDM的观点.
研究的目的:
- 开发和心理测试一个简短的仪器,测量患者对SDM的看法.
- 评估SDM在HAE治疗选择中的有效性.
- 评估SDM作为HAE卫生服务质量指标.
主要方法:
- 美国有10名HAE医生和50名HAE患者参与了这项研究.
- 使用SDM来选择HAE的预防疗法.
- 分析了医生与患者的调查数据,以确定SDM的有效性.
主要成果:
- 90%的人同意对治疗的利弊有明确的解释.
- 92%的人同意医生在理解信息和引起偏好方面的作用.
- 88%的人同意对选择进行彻底权衡,92%的人同意选择联合治疗.
结论:
- 医生们积极实施SDM来管理HAE.
- 这项研究支持SDM在优化HAE治疗选择中的作用.
- SDM提高了患者参与和对HAE治疗决策的满意度.
相关概念视频
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
391
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
391
Rheumatic Heart Disease III: Medical Management
3
Rheumatic heart disease (RHD) management can be divided into two main strategies: prevention and long-term management.Primary PreventionPrimary prevention focuses on timely diagnosis and management of group A streptococcal pharyngitis to prevent acute rheumatic fever. The most widely used antibiotic for treating this condition is intramuscular benzathine penicillin G.Acute Rheumatic Fever TreatmentThe primary treatment goal for a patient diagnosed with acute rheumatic fever is to suppress the...
3
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
141
Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
141
Anticoagulant Drugs: Low-Molecular-Weight Heparins
623
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
623
Heart Failure Drugs: Diuretics
345
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
345
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
135
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
135


